

Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis

S. Bracarda, R. Iacovelli, L. Boni, M. Rizzo, L. Derosa, M. Rossi, L. Galli, G. Procopio, M. Sisani, F. Longo, M. Santoni, F. Morelli, G. Di Lorenzo, A. Altavilla, C. Porta, A. Camerini & B. Escudier on behalf of the Rainbow Group

Ann Oncol 2015; 26: 2107–2113 (doi: 10.1093/annonc/mdv315)

The correct presentation is given below.

In the original article, Figures 1 and 2 were interchanged.




Figure 1. Progression-free survival. Asterisk denotes three patients in the 4/2→2/1 group and two patients in the 2/1 group were not evaluable for PFS.




Figure 2. Overall survival. Asterisk denotes one patient in the 4/2→2/1 group and two patients in the 2/1 group were not evaluable for OS.